

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Connectyx Technologies Holdings Group, Inc.

561-418-7725

curativebiotech.com

SIC – 8731/8733

Annual Report

For the Period Ending: December 31, 2020
(the "Reporting Period")

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

333,000,327

As of September 30, 2020, the number of shares outstanding of our Common Stock was:

322,800,327

As of December 31, 2019, the number of shares outstanding of our Common Stock was:

322,800,327

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Connectyx Technologies Holdings Group, Inc., herein referred to as "CTYX" or the "Company."

The company was formerly known as: Storage Innovation Technologies, Inc. until 10-07; National Boston Medical, Inc. until 5-04; Fragrance Express, Inc. until 10-98; Growth Industries, Inc. until 7-98

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company was originally incorporated on June 29, 1995, in the State of Nevada; the Company, as of October 31, 2007, was reincorporated in the State of Florida and is active in Florida.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

1825 NW Corporate Blvd., Suite 110
Boca Raton, FL 33431

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

2) Security Information

Trading symbol: CTYX
Exact title and class of securities outstanding: Common Stock
CUSIP: 20786Q209
Par or stated value: \$0.0001

Total shares authorized: 1,100,000,000 as of date: December 31, 2020
Total shares outstanding: 333,000,327 as of date: December 31, 2020
Number of shares in the Public Float²: 224,963,739 as of date: December 31, 2020
Total number of shareholders of record: 174 as of date: December 31, 2020

All additional class(es) of publicly traded securities (if any): *N/A*

Trading symbol: _____
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Transfer Agent

Name: Issuer Direct Corporation
Address: One Glenwood Ave, Suite 1001
Address 2: Raleigh, NC 27603
Phone: +1 (919) 481-4000
Email: info@issuereirect.com

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End:

Opening Balance

Date 12/31/18

Common: 322,800,327

Series A Preferred:
34,109,750

Series B Preferred:
293,000

*Right-click the rows below and select "Insert" to add rows as needed.

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>3/5/20</u>	<u>New Issuance</u>	<u>1,500,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	David Alfred Karram and Sarah Margaret Karram	<u>Web Design and Hosting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>4/28/20</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.0016</u>	<u>No</u>	Pamela Bisikirski and John Bisikirski	<u>Marketing</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Ronald W. Bordens, Ph.D	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Michael J. Grace, Ph.D	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/18/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	I Richard Garr, JD	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/8/20</u>	<u>New Issuance</u>	<u>7,000,000</u>	<u>Common</u>	<u>.013</u>	<u>No</u>	Mid Atlantic BioTherapeutics / David Horn, MD	<u>License Execution</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/8/20</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Michael K. Fish	<u>Board Fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Dr. Barry A. Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Ronald W. Bordens, Ph.D	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Michael J. Grace, Ph.D	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	I Richard Garr, JD	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Dr. Barry A. Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/3/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Ivel Realty Associates Corp / Marc Lewis	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>40,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Zabrina Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Theodore Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Samuel Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>

Shares Outstanding on Date of This Report:

<u>Ending Balance:</u>	<u>Ending Balance</u>
Date <u>12/31/20</u>	Common: <u>333,000,327</u>
	Series A Preferred: 134,109,750
	Series B Preferred: 293,000
	Series C Preferred: 30,000,000

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

During the 4th quarter the Company entered into 11 notes payable for a total amount of cash received of \$385,000. The notes are identical and carry a maturity of six months from inception and a 25% fixed interest payment. The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. The notes also carry 10 warrants for each \$1 loaned. These notes are collateralized by Preferred C shares representing 9.24% of the issued and outstanding common stock shares. Two officers holding these Preferred C shares are pledged have pledged them as this collateral.

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
- IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: **Michael K. Fish**
 Title: **Certified Public Accountant**
 Relationship to Issuer: **Director**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

The unaudited financial statements for the period ended 12/31/2020 are attached hereto

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. In November 2020, the Company announced it is changing its name to Curative Biotechnology, Inc. and has applied for the name change and a new trading symbol with the Financial Industry Regulatory Authority, Inc., which is expected take effect in the first quarter of 2021. The Company is focused on developing therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The Company operates on an outsource model, where it's core management group oversees a network of subject matter experts, clinical advisors, manufacturing vendors and regulatory consultants.

- B. Please list any subsidiaries, parents, or affiliated companies.

N/A

- C. Describe the issuers' principal products or services.

Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The Company's principal products are developmental stage therapeutics. <https://www.otcm Markets.com/stock/CTYX/profile>.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company utilizes virtual office space at a cost of \$99 per month.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Paul M. Michaels	Officer and Director	Boca Raton, FL	121,653,800	Series A Preferred	90.7%	See note (1), (2) below
			6,000,000	Series C Preferred	20%	
Dr. Barry A. Ginsberg	Officer and Director	Boca Raton, FL	121,653,800	Series A Preferred	90.7%	See note (1), (2) below
			6,000,000	Series C Preferred	20%	
Michael K. Fish	Director	Miami, FL	200,000	Common	<1%	
Jose A. Bardelas, MD	5% Holder	High Point, NC	27,356,093	Common	8.21%	

I Richard Garr, JD	Officer	Delray Beach, FL	250,000 6,000,000	Common Series C Preferred	≤1% 20%	
Ronald W. Bordens, Ph.D	Officer	Boynton Beach, FL	250,000 6,000,000	Common Series C Preferred	≤1% 20%	
Michael J. Grace, Ph.D	Advisor	Hamilton, NJ	250,000 6,000,000	Common Series C Preferred	≤1% 20%	

- (1) SunMed Advisors LLC purchased the Series A Preferred stock of former President Jon Pevzner and Amanda Schuman on February 24, 2020. Pevzner resigned as an officer and director of the Company on February 24, 2020. At that time Paul M. Michaels was appointed Interim CEO and Director. Dr. Barry A. Ginsberg and Brandon Michaels were also appointed to the Board of Directors. SunMed Advisors LLC is beneficially owned by Paul M. Michaels and Dr. Barry A. Ginsberg.
- (2) Paul M. Michaels and Barry A. Ginsberg were each issued 50,000,000 Series A Preferred on November 11, 2020

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Jonathan Leinwand
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd., Suite 200
Address 2: Aventura, FL 33180
Phone: 954-903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: Michael K. Fish
Firm: Michael K. Fish, CPA PA
Address 1: 7700 N Kendall Dr. #405,
Address 2: Miami, FL 33156
Phone: 305-279-8484

Investor Relations

N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

N/A

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, I Richard Garr certify that:

1. I have reviewed this annual disclosure statement of Connectyx Technologies Holdings Group Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 11, 2021 [Date]

/s/ I Richard Garr [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, I Richard Garr certify that:

1. I have reviewed this annual disclosure statement of Connectyx Technologies Holdings Group Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 11, 2021 [Date]

/s/ I Richard Garr [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

INDEX TO UNAUDITED FINANCIAL STATEMENTS

Balance Sheets	F-2
Statements of Operations	F-3
Statement of Stockholders' Equity	F-4
Statements of Cash Flows	F-5
Notes to Financial Statements	F-6

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Balance Sheets
(Unaudited)
December 31,

	2020	2019
ASSETS		
CURRENT ASSETS		
Cash	\$ 160,607	\$ -
Total current assets	160,607	-
FIXED ASSETS		
Property and equipment	81,515	81,515
Accumulated depreciation	(79,177)	(78,648)
Total fixed assets	2,338	2,867
OTHER ASSETS		
Intangible assets, net of amortization and impairment	140,300	36,908
Total other assets	140,300	36,908
Total Assets	\$ 303,245	\$ 39,775
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	\$ 28,709	\$ 397,103
Third party short term loans and accrued interest	400,824	-
Total current liabilities	429,533	397,103
Total Liabilities	429,533	397,103
Commitments and Contingencies	-	-
STOCKHOLDERS' EQUITY (DEFICIT)		
Preferred stock, \$0.0001 par value, authorized 205,000,000 shares, 134,109,750 Series A: 293,000 Series B and 30,000,000 Series C shares issued and outstanding	16,440	3,440
Common stock, \$0.0001 par value, authorized 1,100,000,000 shares; 333,000,327 and 322,800,327 shares issued and outstanding	33,300	32,280
Additional paid-in capital	3,455,867	3,314,087
Treasury stock	(9,900)	(9,900)
Accumulated deficit	(3,621,995)	(3,697,235)
Total stockholders' equity (deficit)	(126,288)	(357,328)
Total Liabilities and Stockholders' Equity (Deficit)	\$ 303,245	\$ 39,775

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Statements of Operations
(Unaudited)
Year ended December 31,

	<u>2020</u>	<u>2019</u>
REVENUES, net	\$ -	\$ -
COST OF REVENUES	<u>-</u>	<u>-</u>
GROSS MARGIN	-	-
OPERATING EXPENSES:		
General and administrative expenses	35,277	150
Salaries	167,000	-
Professional fees	66,325	-
Depreciation and amortization	<u>5,301</u>	<u>5,301</u>
Total expenses	<u>273,903</u>	<u>5,451</u>
Income (loss) from operations	(273,903)	(5,451)
Other (income) expense:		
Interest expense	15,824	15,882
Impairment of long lived assets	32,136	-
Gain of debt forgiveness	<u>(397,103)</u>	<u>(353,286)</u>
	(349,143)	(337,404)
Net income (loss)	<u>\$ 75,240</u>	<u>\$ 331,953</u>
Income (loss) per weighted average common share	<u>\$0.0002</u>	<u>\$0.0010</u>
Number of weighted average common shares outstanding	<u>326,630,245</u>	<u>322,800,327</u>

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Statement of Stockholders' Equity (Deficit)
(Unaudited)

	Number of Shares		Par Value		Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Common	Preferred	Common	Preferred				
BALANCE, January 1, 2019	322,800,327	34,402,750	\$ 32,280	\$3,440	\$(9,900)	\$ 3,314,087	\$ (4,029,188)	\$ (689,281)
Net income	-	-	-	-	-	-	331,953	331,953
BALANCE, December 31, 2019	322,800,327	34,402,750	32,280	3,440	(9,900)	3,314,087	(3,697,235)	(357,328)
Common shares issued for services	1,700,000	-	170	-	-	36,630	-	36,800
Common shares issued for intangible assets	8,500,000	-	850	-	-	105,150	-	106,000
Preferred Series A issued for services	-	100,000,000	-	10,000	-	-	-	10,000
Preferred Series C issued for services	-	30,000,000	-	3,000	-	-	-	3,000
Net income	-	-	-	-	-	-	75,240	75,240
BALANCE, December 31, 2020	<u>333,000,327</u>	<u>164,402,750</u>	<u>\$ 33,300</u>	<u>\$16,440</u>	<u>\$(9,900)</u>	<u>\$ 3,455,867</u>	<u>\$ (3,621,995)</u>	<u>\$ (126,288)</u>

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Statements of Cash Flows
(Unaudited)
Year ended December 31,

	2020	2019
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income (loss)	\$75,240	\$331,953
Adjustments to reconcile net loss to net cash used by operating activities:		
Depreciation and amortization	5,301	5,301
Share based compensation	49,800	-
Gain on debt forgiveness	(397,103)	(353,286)
Impairment of long lived assets	32,136	-
Changes in operating assets and liabilities		
Increase (decrease) in accounts payable	6,208	-
Increase in accrued expenses	15,823	15,882
Net cash provided by (used in) operating activities	(212,595)	(150)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of intangible assets	(11,800)	-
Net cash (used in) investing activities	(11,800)	-
CASH FLOWS FROM FINANCING ACTIVITIES:		
Payments on third party loans	(48,083)	-
Cash received from third party loans	433,085	150
Net cash (used in) provided by financing activities	385,002	150
Net (decrease) increase in cash	160,607	-
CASH , beginning of period	-	-
CASH , end of period	\$ 160,607	\$ -
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Interest paid in cash	\$ -	\$ -
Income taxes paid in cash	\$ -	\$ -
Non-Cash Financing Activities:		
Common shares issued for intangible assets	\$ 106,000	\$ -

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CTYX) is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

a) Statement of Compliance The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") as issued by the Financial Accounting Standards Board ("FASB").

b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

(c) Cash and equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents.

(d) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.

(e) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any.

Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives.

Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.

(f) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES, continued

(g) Financial Instruments and Fair Value Measurements

ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments.

FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(h) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(i) Revenue Recognition

The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied. The Company’s principal operations are the operation of quick casual restaurants wherein the customer pays for their food upon placing the order. The Illegal Brands operations are the sale of CBD infused water and CBD soluble packets which at present are only sold in the Company’s restaurants. The franchise operations have yet to sell a franchise, but upon such sales will follow the appropriate revenue recognition procedures.

The Company’s financial statements are prepared under the accrual method of accounting. Revenues are recognized when pervasive evidence of an arrangement exists, services have been rendered (product delivered), the sales price is fixed or determinable, and collectability is reasonably assured. This occurs only when the product(s) is ordered and subsequently delivered.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES, continued

(j) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes.

Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

(k) Net income (loss) per share Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period.

(l) Recent Accounting Pronouncements The Company has considered recent accounting pronouncements during the preparation of these financial statements.

NOTE 4 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's financial position and operating results raise substantial doubt about the Company's ability to continue as a going concern, as reflected by the net income of \$75,240 resulting from debt forgiveness of \$397,103, and accumulated deficit of \$3,621,995 through December 31, 2020 and the \$268,926 working capital deficit. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to grow its operations

NOTE 5 - INTANGIBLE ASSETS

During the 4th quarter 2020, the Company acquired the following intangible assets:

(a) Website In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of \$22,500, one-half in cash and one-half in common stock of the Company. The Company expects to amortize this cost over 3 years once it is operational.

(b) Patent rights option In October 2020, the Company entered into an option agreement to purchase certain exclusive license rights for US Patent No. 8,287,505 Ophthalmic Drop Dispensing Tip Assembly, issued October 16, 2012, from IEM, Inc., (IEM), the sole owner of this patent. The cost of this option was payment to the US Patent and Trademark Office (US PTO) of the 7.5 year PTO maintenance fee in the amount of \$1,800, which the Company paid in October 2020.

The Company has until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM \$50,000 in exchange for an exclusive world-wide, royalty free perpetual license. The Company is evaluating the Patent rights, potential products and markets under this Patent.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 5 - INTANGIBLE ASSETS, continued

(c) IMT504 Patent license In October 2020, the Company entered into a license agreement with MidAtlantic BioTherapeutics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immunotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise \$6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A.

The total cost for this license is 20 million shares of the Company's common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at \$91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504.

A principal goal of this license is to obtain a Priority Review Voucher (PRV) issued by the US FDA, and subsequently sell the PRV to a major pharmaceutical company. The Company and MABT will split the proceeds from the sale of such PRV equally.

(d) National Institute of Health (NIH) Patent license In October 2020, the Company entered into an exclusive 24 month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016 and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of glioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with appropriate royalties.

This license calls for the payment of a non-creditable non-refundable license issue royalty of \$10,000, paid ½ at issuance and ½ on the one year anniversary.

NOTE 6 - RELATED PARTY TRANSACTIONS

From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction.

NOTE 7 - NOTES PAYABLE

During the 4th quarter the Company entered into 11 notes payable for a total amount of cash received of \$385,000. The notes are identical and carry a maturity of six months from inception and a 25% fixed interest payment. The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. The notes also carry 10 warrants for each \$1 loaned. These notes are collateralized by Preferred C shares representing 9.24% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral.

NOTE 8 – STOCKHOLDERS EQUITY (DEFICIT)

At December 31, 2020 and 2019, the Company has 1,100,000,000 shares of par value \$0.0001 common stock authorized and 333,000,327 and 322,800,327 issued and outstanding, respectively. At December 31, 2020 and 2019, the Company has 200,000,000 shares of \$0.0001 par value preferred stock authorized and 134,109,750 and 34,109,750 Series A; 293,000 Series B and 30,000,000 and 0 Series C issued and outstanding, respectively. The preferred shares have the following respective rights and privileges:

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 8 – STOCKHOLDERS EQUITY (DEFICIT), continued

Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; is convertible into common stock aggregating 35% of the total issued and outstanding common shares at conversion date post conversion; are redeemable for the greater of 45% of the total market value of the common share or the calculation of the book value of the Company made by an independent audit firm or \$5,000,000.

Series B Preferred are convertible in common shares of common stock at a conversion price of \$0.0075 per share; are redeemable at a price of 125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation.

Series C Preferred are convertible into at the record date; is convertible into common stock aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carry one vote for each common share that the Series C is convertible into at the record date.

During the 4th quarter 2020, the Company issued 1,700,000 shares of common stock in exchange for services valued at \$36,800, or \$0.0216 per share. During the 4th quarter 2020, the Company issued 8,500,000 shares of common stock to acquire intangible assets valued at \$106,000, or \$0.0125 per share.

NOTE 9 - WARRANTS

The Company issued 3,850,000 warrants for the purchase of common stock of the Company in conjunction with the short term debt at the rate of 10 warrants for each \$1 loaned. These warrants carry an expiration of thirty six months from issuance; an exercise price of \$0.05 per share and are exercisable immediately.

During the 4th quarter the Company issued 6,750,000 warrants to two people for services. These warrants carry an expiration of 60 months from issuance and an exercise price of \$0.05 per share.

NOTE 10 - FINANCIAL INSTRUMENTS

(a) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company relies on cash flows generated from operations, as well as injections of capital through the issuance of the Company's capital stock to settle its liabilities when they become due.

(b) Interest Rate Risk The Company is not exposed to significant interest rate risk due to the short-term maturity of its monetary current assets and current liabilities.

NOTE 11 - IMPAIRMENT OF LONG LIVED ASSETS

During the 4th quarter 2020, the Company elected to abandon the intangible assets it had been attempting to commercialize under prior management. As such the Company recorded an impairment of the remaining unamortized balance of \$32,136.

NOTE 12 - INCOME TAXES

The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 12 - INCOME TAXES, continued

The components of income tax provision (benefit) related to continuing operations are as follows at December 31:

	<u>2020</u>	<u>2019</u>
Current	\$ -	\$ -
Deferred	\$ -	\$ -
Total tax provisions	<u>\$ -</u>	<u>\$ -</u>

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31:

	<u>2019</u>	<u>2018</u>
U.S. Federal statutory income tax rate	(21)%	(21)%
State income tax, net of federal benefit	(4.5)%	(4.5)%
Valuation allowance	25.5%	25.5%
	<u>0.0%</u>	<u>0.0%</u>

The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31:

	<u>2020</u>	<u>2019</u>
Deferred tax assets:		
Net operating loss carry forwards	\$ 780,387	\$ 819,122
Stock based compensation	11,033	-
Other	-	-
Total	<u>791,420</u>	<u>819,122</u>
Deferred tax liabilities:	-	-
Less: valuation allowance	<u>(791,420)</u>	<u>(819,122)</u>
Net deferred tax assets	<u>\$ -</u>	<u>\$ -</u>

The change in valuation allowance was \$22,098 and (\$73,544) for the years ended December 31, 2020 and 2019, respectively. We have recorded a 100% valuation allowance related to the deferred tax asset for the income from operations. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 12 - INCOME TAXES, continued

In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2020 and 2019, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

NOTE 13 - COMMITMENTS AND CONTINGENCIES

(a) Other The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company's financial position or results of operations.

NOTE 14 - CONCENTRATIONS OF CREDIT RISK

(a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had no cash balance in excess of FDIC insured limits at December 31, 2019 and 2018.

NOTE 15 - SUBSEQUENT EVENTS

(a) Intangible assets In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases.

This license requires two separate royalty streams of payments.

First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of \$8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional unreimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary.

Second is an ongoing royalty schedule: an initial royalty of \$5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable non-creditable royalty of \$45,000. There are three benchmark royalties - \$75,000 upon the initiation of the first Phase 2 Clinical Study; \$300,000 upon the completion of Phase 3 Clinical Study and \$600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of \$100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

(b) Notes payable In January and February 2021 the Company entered into 4 additional notes payable under identical notes in the amount of \$180,000. The notes are identical and carry a maturity of six months from inception and a 25% fixed interest payment. The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. The notes also carry 10 warrants for each \$1 loaned.

These notes are collateralized by Preferred C shares representing 4.32% of the issued and outstanding common stock shares. Two officers holding these Preferred C shares are pledged have pledged them as this collateral.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Financial Statements
(Unaudited)

NOTE 15 - SUBSEQUENT EVENTS, continued

(c) Stockholders equity In January 2021, the Company issued 27,066,666 shares of common stock upon the conversion of 203,000 Series B preferred stock. In February 2021, the Company issued 9,500,000 shares of common stock upon the exercise of 9,500,000 warrants.

(d) Warrants In January 2020, the Company issued 5,000,000 warrants with an exercise price of \$0.05 per share; an expiration 60 months after issuance and are exercisable immediately. In January and February 2021, the Company issued 1,800,000 warrants with an exercise price of \$0.05 per share; an expiration of thirty six months and are exercisable immediately, in conjunction with the notes payable.

In February 2021, holders of 10,500,000 warrants exercised the warrants. The Company received \$525,000 in cash and issued 10,500,000 shares of common stock. 6,900,000 warrants remain outstanding.